# SilverArc Capital

> SilverArc Capital is a VC fund backing Biotechnology, Health Care and Medical. See 17 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 17
- Last investment: Jul 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: https://silverarccapital.com/

SilverArc Capital is an investment firm focused on healthcare.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 71% |
| Health Care | 10 | 59% |
| Medical | 7 | 41% |
| Therapeutics | 5 | 29% |
| Pharmaceutical | 3 | 18% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 9 | 53% |
| Series A | 2 | 12% |
| Seed | 1 | 6% |
| Series B | 1 | 6% |
| Series C | 1 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 53% |
| China | 1 | 6% |
| Canada | 1 | 6% |
| Israel | 1 | 6% |
| Latvia | 1 | 6% |

6 countries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Processa Pharmaceuticals | Processa Pharmaceuticals operates as a pharmaceutical company. The company focuses on development of drug products that are intended to improve the survival and quality of life for patients who have unmet medical need. | $200M | Post-IPO Equity | Jul 29, 2026 |  |
| Jasper Therapeutics | Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant. | $132M | Post-IPO Equity | Jul 16, 2026 |  |
| Quince Therapeutics | Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M | Post-IPO Equity | May 18, 2026 |  |
| Cellectar Biosciences | Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignantcells.Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin. | $35M | Post-IPO Equity | May 05, 2026 |  |
| Congruence Therapeutics | Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $39.5M | Venture - Series Unknown | Mar 19, 2026 |  |
| CORXEL Pharmaceuticals | Jixing Pharmaceuticals develops innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases. | $287M | Series D | Jan 22, 2026 |  |
| Manifold | Manifold is a software company that provides machine learning tools designed to help organizations analyze operational data and support decision making in industrial and energy environments. The platform processes time-series data from sensors, equipment, and control systems to identify patterns, detect anomalies, and generate forecasts related tosystem performance and reliability. Manifold enables users to build, deploy, and monitor predictive models without extensive manual coding, allowing data science workflows to integrate with existing operational systems. The software supports use cases such as asset monitoring, predictive maintenance, and optimization of complex processes through data analysis. Manifold focuses on translating raw operational data into structured insights that support planning and operational oversight. | $18M | Series B | Dec 18, 2025 |  |
| Modulight Bio | Modulight Bio develops an optogenetic platform intended for the treatment of neurological disorders. The company’s technology uses optogenetics to modulate neuronal activity by targeting synaptic mechanisms. Its approach relies on endogenous cellular processes to adjust neural signaling with spatial and temporal precision. The platform is designedto address conditions associated with abnormal or excessive neuronal activation. | $12M | Seed | Nov 13, 2025 |  |
| Congruence Therapeutics | Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $32M | Venture - Series Unknown | Sep 04, 2025 |  |
| Aardvark Therapeutics | Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics was founded by Tien Lee in 2017. | $85M | Series C | May 09, 2024 |  |

10 of 17 investments shown.

## Co-investors
- [Nantahala Capital Management](https://shizune.co/investors/profile/nantahala-capital-management) — VC Fund, 5 deals together
- [Amplitude Venture Capital](https://shizune.co/investors/profile/amplitude-venture-capital) — VC Fund, 3 deals together
- Armistice Capital — VC Fund, 3 deals together
- [Balyasny Asset Management](https://shizune.co/investors/profile/balyasny-asset-management) — VC Fund, 3 deals together
- [Bdc Thrive venture](https://shizune.co/investors/profile/bdc-thrive-venture) — VC Fund, 3 deals together
- [Fonds de solidarité FTQ](https://shizune.co/investors/profile/fonds-de-solidarit-ftq) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does SilverArc Capital invest in?

SilverArc Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did SilverArc Capital last invest?

The most recent investment recorded for SilverArc Capital closed in Jul 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co